Abstract:Cardiovascular diseases and hypertension in particular are major health risks worldwide and the improvement on their treatment will be beneficial for the human health. AT1R antagonists belong to the sartans family that targets the renin-angiotensin aldosterone system (RAAS) through blocking the hormone angiotensin II to exert its detrimental effects in pathological states. As a consequence, they are beneficial to treat hypertension, diabetes related kidney failure and hyperaemic episodes. Long unbiased Molecular Dynamics (MD) simulations are performed in order to explore candesartan's possible 2D and 3D diffusion mechanisms towards AT1R receptor. 3D diffusion mechanism is referred to the direct binding of the AT1 antagonist candesartan to the AT1R 3D structure (PDB ID: 4YAY). 2D diffusion mechanism involves first, the incorporation of candesartan in the bilayer core and then its localization on the AT1R binding cavity, through a diffusion mechanism. The obtained results indicate that membranes interact significantly with the neutral form of candesartan, which is indeed approaching the receptors' active site through diffusion via the lipids. On the other hand, the deprotonated form of the drug is interacting with AT1R's extracellular loop and fails to enter the membrane, pointing out the importance of the pH microenvironment around the receptor. To validate the calculated diffusion coefficients of the drug in the lipid bilayers 2D DOSY NMR experiments were recorded and they were in good agreement. Information on the impact that has the interaction of candesartan with the membrane is very important for the rationally design and development of potent ARBs. Thus, its conformational features as well as its localization in the membrane core have to be thoroughly explored.

In vitro effect of sanguinarine alkaloid on binding of [3H]candesartan to the human angiotensin AT1 receptor

Protective Effect of Losartan on Endothelial Cells Exposed to High Glucose Levels in Vitro

Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor.

Effects of irbesartan on cell calcium transport protein in spontaneously hypertensive rats

Exploring the role of the membrane bilayer in the recognition of candesartan by its GPCR AT1 receptor

Candesartan Inhibits Sinoaortic Denervation-Induced Cardiovascular Hypertrophy in Rats.

Candesartan, losartan and valsartan Zn(II) complexes interactions with bovine serum albumin

[Effect of Irbesartan on Focal Cerebral Ischemia in Rats].

Characterizing the Binding Mechanism of Sparsentan to the Type-2 Angiotensin II Receptor Using AutoDock Vina

Effect of long-term angiotensin II type I receptor antagonism on peripheral and coronary vasomotion

The carboxyl group of candesartan contributes to the potent inverse agonist activity and insurmountable inhibition of candesartan

Systematic Characterization of AT1 Receptor Antagonists with Label-Free Dynamic Mass Redistribution Assays.

Effect of captopril or verapamil on intracellular sodium in cultured vascular smooth muscle cells

Studies on pharmacokinetic properties and intestinal absorption mechanism of sanguinarine chloride: in vivo and in situ

Sanguinarine Attenuates Collagen-Induced Platelet Activation and Thrombus Formation

Inhibitory Effect of Apigenin on Losartan Metabolism and CYP2C9 Activity in vitro.

Antihypertensive Effects of a New Angiotensin Type 1 Receptor Antagonist I B on Rats

Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes

In vitro effect of cilazaprilat on sodium-potassium transport systems in human erythrocytes

EFFECT OF ANGIOTENSIN II RECEPTOR ANTAGONIST AND ENDOTHELIN RECEPTOR ANTAGONIST ON NITROGLYCERIN TOLERANCE IN RATS

Losartan and metabolite EXP3179 activate endothelial function without lowering blood pressure in AT2 receptor KO mice.